Technical Report abstract

Nature Medicine 14, 199 - 204 (2008)
Published online: 3 February 2008 | doi:10.1038/nm1713

Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation

Nathan W Bartlett1,10, Ross P Walton1,10, Michael R Edwards1, Juliya Aniscenko1, Gaetano Caramori2, Jie Zhu3, Nicholas Glanville1, Katherine J Choy4, Patrick Jourdan1,9, Jerome Burnet1,9, Tobias J Tuthill5, Michael S Pedrick6, Michael J Hurle6, Chris Plumpton6, Nigel A Sharp6, James N Bussell6, Dallas M Swallow7, Jurgen Schwarze1, Bruno Guy8, Jeffrey W Almond8, Peter K Jeffery3, Clare M Lloyd4, Alberto Papi2, Richard A Killington5, David J Rowlands5, Edward D Blair6,9, Neil J Clarke6 & Sebastian L Johnston1

Rhinoviruses cause serious morbidity and mortality as the major etiological agents of asthma exacerbations and the common cold. A major obstacle to understanding disease pathogenesis and to the development of effective therapies has been the lack of a small-animal model for rhinovirus infection. Of the 100 known rhinovirus serotypes, 90% (the major group) use human intercellular adhesion molecule-1 (ICAM-1) as their cellular receptor and do not bind mouse ICAM-1; the remaining 10% (the minor group) use a member of the low-density lipoprotein receptor family and can bind the mouse counterpart. Here we describe three novel mouse models of rhinovirus infection: minor-group rhinovirus infection of BALB/c mice, major-group rhinovirus infection of transgenic BALB/c mice expressing a mouse-human ICAM-1 chimera and rhinovirus-induced exacerbation of allergic airway inflammation. These models have features similar to those observed in rhinovirus infection in humans, including augmentation of allergic airway inflammation, and will be useful in the development of future therapies for colds and asthma exacerbations.

  1. Department of Respiratory Medicine, UK National Heart and Lung Institute, Wright Fleming Institute of Infection and Immunity, and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, Norfolk Place, London W2 1PG, UK.
  2. Research Centre on Asthma and Chronic Obstructive Pulmonary Disease, University of Ferrara, Ferrara 44100, Italy.
  3. Department of Population Genetics and Gene Therapy, National Heart and Lung Institute, Imperial College London, Royal Brompton Campus, London SW3 6NP, UK.
  4. Leukocyte Biology Section, National Heart and Lung Institute, Imperial College London, South Kensington, London SW7 2AZ, UK.
  5. Institute for Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK.
  6. GlaxoSmithKline Medicines Research Centre, Stevenage SG1 2NY, UK.
  7. The Galton Laboratory, Department of Biology, University College London, London WC1E 6BT, UK.
  8. Sanofi Pasteur, S.A., Avenue Pont Pasteur, 69007 Lyon, France.
  9. Present addresses: Integrated Medicines, Topfield House, Ermine Street, Caxton, Cambridge CB3 8PQ, UK (E.D.B.); Labtech France, 13 rue Titon, 75011 Paris, France (P.J.); Molecular Oncology Unit, John Vane Science Center, Charterhouse Square, London EC1M 6BQ, UK (J.B.).
  10. These authors contributed equally to this work.

Correspondence to: Sebastian L Johnston1 e-mail:


These links to content published by NPG are automatically generated.


Treatment strategies for allergy and asthma

Nature Reviews Immunology Review (01 Mar 2008)

Relationship of viral infections to wheezing illnesses and asthma

Nature Reviews Immunology Perspective (01 Feb 2002)

See all 25 matches for Reviews


Flu strikes the hygiene hypothesis

Nature Medicine News and Views (01 Mar 2004)